Imunon, Inc.
IMNN evidence brief
What we can confirm
- Market Cap:
- $8.2M
What it means
What to watch
Prepared research question
What matters most for IMNN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMNN
Imunon, Inc. (IMNN) is a clinical-stage biotechnology company focused on developing its lead candidate, IMNN-001, a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer, currently in a pivotal Phase 3 trial.
Key risk: Cash runway risk
Market Cap
$8.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 4 clinical trials for Imunon, Inc..
Imunon, Inc. (IMNN) is a clinical-stage biotechnology company focused on developing its lead candidate, IMNN-001, a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer, currently in a pivotal Phase 3 trial.
- Lead candidate IMNN-001 is in a pivotal Phase 3 OVATION 3 trial for newly diagnosed advanced ovarian cancer [news · 2026-08-26].
- Enrollment in the Phase 3 OVATION 3 trial is expected to be completed by the first half of 2029 [news · 2026-08-11].
- As of December 31, 2025, the company had cash and cash equivalents of $8.8 million and incurred a net loss of $14.5 million for the year [sec_mda · as of 2026-03-31].
- The company has incurred approximately $421 million of cumulative net losses as of December 31, 2025 [sec_mda · as of 2026-03-31].
- The company does not expect to generate any revenue from product sales in the next several years, if at all [sec_mda · as of 2026-03-31].
What works
- IMNN-001 is described as the first frontline immunotherapy to demonstrate potential for a clinically meaningful overall survival benefit in newly diagnosed advanced ovarian cancer [news · 2026-03-31].
- Enrollment in the Phase 3 OVATION 3 trial is running ahead of plan, supported by strong interest from investigators [news · 2026-03-31][news · 2026-08-19].
- The company is hosting an R&D Day in September 2026 to highlight Phase 3 trial progress and clinical data, indicating active stakeholder engagement [news · 2026-08-26].
What to weigh
- The company has no product revenue and does not expect any for several years, if at all [sec_mda · as of 2026-03-31].
- As of December 31, 2025, cash and cash equivalents were only $8.8 million, with a net loss of $14.5 million for the year [sec_mda · as of 2026-03-31].
- The company has substantial future capital requirements to complete the Phase 3 trial and cannot estimate when or if cash inflows from product sales will occur [sec_mda · as of 2026-03-31].
- Cumulative net losses total approximately $421 million as of December 31, 2025, highlighting a long history of operating at a deficit [sec_mda · as of 2026-03-31].
From the filings
Quoted directly from source documents.
IMNN-001 is in a Phase 3 pivotal trial for advanced ovarian cancer.
“IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated i”
News · November 10, 2025
No near-term product revenue expected.
“We have not generated and do not expect to generate any revenue from product sales in the next several years, if at all.”
SEC MD&A · March 31, 2026
Enrollment in Phase 3 trial is ahead of plan.
“Enrollment in the OVATION 3 Study, IMUNON's Phase 3 pivotal trial for IMNN-001, remains ahead of plan”
News · March 31, 2026
Catalyst timeline
- 2018-09-05 · Phase 2 Start (IMNN-001 + NACT in ovarian cancer) — Initiation of a Phase I/II study evaluating IMNN-001 with neoadjuvant chemotherapy in newly diagnosed advanced ovarian cancer.
- 2023-02-10 · Phase 2 Start (IMNN-001 + bevacizumab + NACT) — Start of a Phase II study evaluating IMNN-001 with bevacizumab and neoadjuvant chemotherapy in advanced ovarian cancer.
- 2024-06-04 · Phase 2 Start (dose-escalation study) — Initiation of a Phase 1/2 dose-escalation study to evaluate safety and immunogenicity of IMNN-001.
Risks & what to watch (4)›
Key risks
- Cash runway risk — Only $8.8 million cash as of Dec 31, 2025, with a $14.5M annual net loss, raising questions about funding the Phase 3 trial to completion [sec_mda · as of 2026-03-31].
- No product revenue — Company does not expect product revenue for several years, if ever, meaning it remains fully dependent on external financing [sec_mda · as of 2026-03-31].
- Phase 3 trial uncertainty — Completion costs and timeline for the Phase 3 registrational trial cannot be estimated with certainty [sec_mda · as of 2026-03-31].
- Cumulative losses — Approximately $421 million in cumulative net losses as of Dec 31, 2025, indicating a long history of negative cash flow [sec_mda · as of 2026-03-31].
What to watch
- Phase 3 OVATION 3 trial enrollment progress and completion timeline [news · 2026-08-11].
- Upcoming R&D Day on September 23, 2026, where clinical data and patient perspectives will be shared [news · 2026-08-26].
- Any new financing or partnership announcements given the limited cash runway [sec_mda · as of 2026-03-31].
- Overall survival data updates from the Phase 3 trial, as the pivotal endpoint [news · 2026-03-31].
Sources: Catalysts · News · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run Imunon, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Imunon, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
19
Total value held
$1.6M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 348,330 | $1.0M |
| riverview capital advisers, llc | 34,364 | $248K |
| vanguard capital management llc | 48,056 | $141K |
| geode capital management, llc | 33,211 | $98K |
| vanguard fiduciary trust co | 13,269 | $39K |
| blackrock, inc. | 4,464 | $13K |
| wells fargo & company/mn | 3,342 | $10K |
| morgan stanley | 3,035 | $9K |
| tower research capital llc (trc) | 1,866 | $5K |
| sbi securities co., ltd. | 1,027 | $3K |
Showing top 10 of 19 institutional holders of Imunon, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 3.6%
- Days to cover
- 0.7
- Shares short
- 142,264
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMNN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Imunon, Inc.?
Imunon, Inc. (IMNN) is a clinical-stage biotechnology company focused on developing its lead candidate, IMNN-001, a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer, currently in a pivotal Phase 3 trial.
Who is the CEO of Imunon, Inc.?
Dr. Stacy R. Lindborg Ph.D. is the chief executive officer of Imunon, Inc. (IMNN).
Where is Imunon, Inc. headquartered?
Imunon, Inc. (IMNN) is headquartered in Lawrenceville, NJ, United States.
What therapeutic areas does Imunon, Inc. focus on?
Imunon, Inc. develops therapies across Oncology, Immunology, Infectious Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.